Search Resources — Somali Digital Library

Journals 2023 EN

Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021

Kanyin Liane Ong · Lauryn K Stafford · Susan A. McLaughlin +792 more

Elsevier BV

View

Journals 2023 EN

WS09.01 Extending the success of Trikafta to rare mutations - insights from CFTR structure and modulator binding

N. Stanleigh · Michal Gur · Eitan Kerem +2 more

Elsevier BV

View

Journals 2023 EN

P052 Efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with normal/near normal FEV1 (≥70%)

Karin YaacobyBianu · Adi Dagan · M. Cohen-Cymberknoh +6 more

Elsevier BV

View

Journals 2023 EN

P077 Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation

Malena CohenCymberknoh · I. Sadras · Eitan Kerem +19 more

Elsevier BV

View

Journals 2023 EN

P081 Theratyping – extending the success of highly effective CFTR modulators to rare mutations

Mordechai Pollak · Yazeed Toukan · Ronen BarYoseph +4 more

Elsevier BV

View

Journals 2023 EN

P095 A phase 1b/2a randomized, double-blind, placebo-controlled, multicentre study evaluating nebulized phage therapy in cystic fibrosis subjects with chronic Pseudomonas aeruginosa pulmonary infection

Urania Rappo · M. Kahan-Hanum · Xilla T. Ussery +16 more

Elsevier BV

View

Journals 2023 EN

116 First-in-human clinical trial with SPL84, an antisense oligonucleotide for treatment of people with cystic fibrosis with the 3849 +10 Kb C - > T mutation

Yoseph Caraco · Maor Wanounou · Lee Friedman +3 more

Elsevier BV

View

Journals 2023 EN

126 A phase 1b/2a randomized, double-blind, placebo-controlled, multicenter study evaluating nebulized phage therapy in people with cystic fibrosis with chronic Pseudomonas aeruginosa pulmonary infection

Urania Rappo · M. Kahan-Hanum · Xilla T. Ussery +16 more

Elsevier BV

View

Journals 2023 EN

235 Reducing MUC5AC or MUC5B expression using antisense oligonucleotides as a therapeutic approach for cystic fibrosis and other muco-obstructive diseases

Yifat S. Oren · C. Stampfer · R. Elgrabli +8 more

Elsevier BV

View

Journals 2023 EN

236 SPL84, an antisense oligonucleotide modulating the 3849+10 kb C-T splicing defect, efficiently penetrates and restores CFTR function when treated through the apical side of primary human bronchial epithelial cells

Ofra Barchad-Avitzur · Yifat S. Oren · C. Stampfer +3 more

Elsevier BV

View